Ziemssen, F., Cruess, A., Dunger-Baldauf, C., Margaron, P., Snow, H., & Strain, W. D. (2017). Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment. Eur Endocrinol.

Ziemssen, Focke, Alan Cruess, Cornelia Dunger-Baldauf, Philippe Margaron, Howard Snow, ja William David Strain. "Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 Mg PRN Versus Laser Treatment." Eur Endocrinol 2017.

Ziemssen, Focke, et al. "Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 Mg PRN Versus Laser Treatment." Eur Endocrinol 2017.